Trial: 201505024

An Open-Label, Multicenter, Phase I/II trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia



Principal Investigator

Bartlett, Nancy

Disease Site

Lymphoid Leukemia; Non-Hodgkin Lymphoma

Learn more about this study at: